What if drug
discovery
started
with patients?
We've taken a first principles approach to tackle the translational complexity of biology in drug discovery and develop a pipeline of therapeutic antibodies with compelling patient-derived data before entering the clinic. We are focused on addressing areas of high unmet need in cancer.
OncoPrecision is a platform therapeutics company leveraging high-throughput biology + AI/ML to integrate patients at every step of the discovery and development journey, from hypothesis generation through lead optimization and beyond.
The current oncology drug discovery paradigm integrates patients too late in the journey, leading to the failure of >95% of novel therapeutics programs.1
Founded by pioneers in the development of high-throughput screening technologies, we've built a patient-centric engine to increase the probability of success in drug discovery with models that are highly translational and predictive of clinical outcome.
1 IQVIA, 'Global Oncology Trends:
Outlook to 2027', May 2023
Patient-derived models to unlock translational
phenotypic insights at a single-cell resolution.
Capturing Heterogeneity
In contrast to other patient-derived models, such as organoids, our PMAs do not rely on amplification and maintain the original ratios and clonality of malignant cells, as well as healthy cells and immune infiltrate from the tumor microenvironment.
Patient-derived models to unlock translational phenotypic insights at a single-cell resolution.
We're building a differentiated therapeutic antibody pipeline based on proprietary patient-derived data; from therapeutic hypothesis to lead optimization and beyond. We focus primarily on novel biology/first-in-class programs.
ONC001 CD64
Modality:
ADC
Indication:
Monocytic Leukemia
Tumor-Associated Macrophages
Stage:
Preclinical Development
ONC002
Modality:
BsAb
Indication:
a
Tumor-Associated Macrophages Immunity
& Inflammation
Stage:
Preclinical Development
ONC003
Modality:
ADC
Indication:
Pan-Cancer
Stage:
Target Validation
ONC007
Modality:
ADC/BsAb
Indication:
Multiple Myeloma
Stage:
Target ID
Program
ONC001
CD64
ONC002
ONC003
ONC007
Modality
ADC
BsAb
ADC
ADC/BsAb
Indication
Monocytic Leukemia
Tumor-Associated Macrophages
Tumor-Associated Macrophages
Immunity & Inflammation
Pan-Cancer
Multiple Myeloma
Validation
Development
Studies
a
Our company was spun out of Dr. Gastón Soria's Synthetic Lethality in Cancer Lab, with a successful track record of Target ID and Drug Discovery collaborations with leading global pharmaceutical companies. Our Mission is supported by a distinguished advisory board of leaders whose work impacts millions of patients worldwide.
Francisco Molinari
Former CEO, AMEGA Biotech
Gail J. Roboz, MD
Director of Clinical and Translational Leukemia, Weill Cornell Medicine and NewYork-Presbyterian Hospital
Gwen Nichols, MD
EVP & Chief Medical Officer, Leukemia & Lymphoma Society
Israel Gloger, OBE, PhD, FRSB
Founder Emeritus, Trust in Science, GSK
Jorge Solimano, MD
Head of Hematology, CEMIC
Robert J. Schneider, PhD
Associate Dean for Therapeutics Alliances, NYU Langone Health
Stefan Oschmann, PhD
Former Chairman & CEO, Merck KGaA
Partnerships
Pharma
We welcome partnership opportunities to leverage our platform to discover and develop novel antibody-based treatments with a high probability of success, thanks to our translational patient-centric biology models.
We are enthusiastic about partnering with leading pharmaceutical companies to accelerate our path to patient impact with our growing pipeline of therapeutic antibodies.
Clinical
Through multiple partnerships with leading cancer centres in North and South America, we are advancing various clinical validation studies to enhance the predictive power of our platform and deploy our technology to help today's and tomorrow's cancer patients.
